The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

S&P 500 added 0.23% to finish Thursday’s session at 7,039, while the Nasdaq Composite rose 0.36% to close at 24,103. Across telehealth and online health services, peers were mixed: Teladoc Health ...

・The FDA scheduled advisory meetings on July 23-24 to review several peptide substances for possible inclusion on the 503A Bulks List. ・BofA raised its price target in HIMS to $25 from $21, citing ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Hims & Hers Health stock climbed as much as 11% Monday, continuing a week-long rally after the FDA announced a meeting to discuss considering easing peptide regulation—a push repeatedly championed by ...

Investing.com - Leerink Partners reiterated a Market Perform rating and $25.00 price target on Hims and Hers (NYSE:HIMS) following news of an upcoming Advisory Committee meeting on injectable peptides ...

Hims & Hers Health (NYSE:HIMS), a consumer-focused telehealth platform offering prescription and non-prescription health products, closed Thursday at $26.98, up 11.07%. The stock moved higher as ...